Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > BUSINESS
BUSINESS
- Takeda to Transform Osaka Plant into Specialty Manufacturing Site for Leuplin
December 1, 2014
- Sandoz Launches Biosimilar of G-CSF Product Gran; Comarkets with Sawai
December 1, 2014
- Mochida Applies for Additional Indication of Social Anxiety Disorder for Lexapro
December 1, 2014
- EPS Gives 400 Workers CDISC Training to Set Itself Apart from Rival CROs
November 28, 2014
- MSD, Kyorin to Comarket Allergy Drug Desloratadine in Japan
November 28, 2014
- Novartis Files for Japan Approval of Equa-Metformin Combination Drug
November 28, 2014
- Kyowa Kirin Launches Sustained-Duration G-CSF Product G-Lasta
November 28, 2014
- Daiichi Sankyo Aims for No. 1 with Lixiana in Novel Oral Anticoagulant Market: Sales Division Head
November 28, 2014
- Allergan Targeting 10 Billion Yen Sales for GlashVista in Japan Eyelash Care Market
November 28, 2014
- ASKA Aims for 50% Share of Generic Candesartan Market through Blopress AG: President
November 27, 2014
- Janssen Files NDA for Anticancer Agent Ibrutinib in Japan
November 27, 2014
- Oncolys Files IND Application for Novel Cancer Treatment OBP-801 in US
November 27, 2014
- Kaken Banking on Clenafin to Boost Dermatology Biz
November 27, 2014
- Bulk Antibody Production Efficiency Up 10-fold, Production Costs Down “Several-fold” Since 2002: Chugai
November 26, 2014
- Amgen Calls Off Clinical Studies of Rilotumumab for Gastric Cancer
November 26, 2014
- MSD to Ensure Appropriate Use of Insomnia Drug Belsomra
November 26, 2014
- Eisai Launches Halaven in Brazil
November 26, 2014
- Eisai Launches Fycompa in Hong Kong
November 26, 2014
- MSD Seeks Japan Regulatory Approval for Once-Weekly DPP-4 Inhibitor
November 25, 2014
- Rushed Settlements Dragged Down Drug Delivery Prices: Vital KSK Exec
November 25, 2014
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…